MHRA-100184-PIP01-21

Key Facts

Active Substance
Active Substance:
  • BENRALIZUMAB
Invented Name
  • FASENRA
  • FASENRA
  • FASENRA
  • FASENRA
  • FASENRA
  • FASENRA
PIP Number MHRA-100184-PIP01-21
Pharmaceutical form(s)
  • Solution for injection
  • Age-appropriate dosage form for parenteral use
Therapeutic area
Therapeutic area:
  • Pneumology - Allergology
Conditions / Indications
Conditions / Indications:
  • Non-cystic fibrosis bronchiectasis with an eosinophilic phenotype
Route(s) of administration
Route(s) of administration:
  • Subcutaneous use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):BENRALIZUMAB.pdf
Published Date 17/05/2022